Literature DB >> 19847149

Reduction in rotavirus after vaccine introduction--United States, 2000-2009.

.   

Abstract

Worldwide, rotavirus is the leading cause of severe acute diarrhea in children aged <5 years. In the United States, before introduction of a live, oral pentavalent rotavirus vaccine (RV5) in 2006, rotavirus caused an estimated 20 to 60 deaths, 55,000 to 70,000 hospitalizations, 205,000 to 272,000 emergency department visits, and 410,000 outpatient visits annually. Before 2000, rotavirus had a predictable winter-spring seasonality and geographic pattern in the United States, with activity beginning in the West census region during December-January, extending across the country, and ending in the Northeast region during May-June. A similar but less pronounced trend was observed during 2000-2006. To characterize trends and compare the 2007-08 and 2008-09 rotavirus seasons with the prevaccine period 2000-2006, CDC analyzed data from the National Respiratory and Enteric Viruses Surveillance System (NREVSS). The results indicated that the 2007-08 and 2008-09 seasons were both shorter and later than the median during 2000-2006. The 2008-09 season had 15% more positive rotavirus test results than the 2007-08 season, but the number of positive test results during each season was substantially lower than the median observed during 2000-2006. Continued surveillance is needed to characterize the effect of routine childhood rotavirus vaccination on rotavirus disease in U.S. children.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19847149

Source DB:  PubMed          Journal:  MMWR Morb Mortal Wkly Rep        ISSN: 0149-2195            Impact factor:   17.586


  28 in total

Review 1.  Immune responses to rotavirus infection and vaccination and associated correlates of protection.

Authors:  Ulrich Desselberger; Hans-Iko Huppertz
Journal:  J Infect Dis       Date:  2011-01-15       Impact factor: 5.226

Review 2.  The impact of new vaccine introduction on immunization and health systems: a review of the published literature.

Authors:  Terri B Hyde; Holly Dentz; Susan A Wang; Helen E Burchett; Sandra Mounier-Jack; Carsten F Mantel
Journal:  Vaccine       Date:  2012-08-29       Impact factor: 3.641

3.  Adoption of rotavirus vaccine by U.S. physicians: progress and challenges.

Authors:  Sean T O'Leary; Umesh D Parashar; Lori A Crane; Mandy A Allison; Shannon Stokley; Brenda L Beaty; Michaela Brtnikova; Laura P Hurley; Allison Kempe
Journal:  Am J Prev Med       Date:  2013-01       Impact factor: 5.043

4.  Determining the effectiveness of the pentavalent rotavirus vaccine against rotavirus hospitalizations and emergency department visits using two study designs.

Authors:  Stephanie Donauer; Daniel C Payne; Kathryn M Edwards; Peter G Szilagyi; Richard W Hornung; Geoffrey A Weinberg; James Chappell; Caroline B Hall; Umesh D Parashar; Mary Allen Staat
Journal:  Vaccine       Date:  2013-04-12       Impact factor: 3.641

Review 5.  Rotavirus infections and vaccines: burden of illness and potential impact of vaccination.

Authors:  Keith Grimwood; Stephen B Lambert; Richard J Milne
Journal:  Paediatr Drugs       Date:  2010-08-01       Impact factor: 3.022

6.  Immunogenicity and safety of the pentavalent human-bovine (WC3) reassortant rotavirus vaccine (PRV) in Indian infants.

Authors:  M R Lokeshwar; Sheila Bhave; Ashok Gupta; V K Goyal; Anuj Walia
Journal:  Hum Vaccin Immunother       Date:  2013-01       Impact factor: 3.452

7.  Hospital-based surveillance to estimate the burden of rotavirus gastroenteritis in children below five years of age in Romania.

Authors:  Ioana Alina Anca; Florentina Ligia Furtunescu; Doina Pleşca; Adrian Streinu-Cercel; Sorin Rugină; Katsiaryna Holl
Journal:  Germs       Date:  2014-06-02

8.  Impact of rotavirus vaccination in regions with low and moderate vaccine uptake in Germany.

Authors:  Sandra Dudareva-Vizule; Judith Koch; Matthias An der Heiden; Doris Oberle; Brigitte Keller-Stanislawski; Ole Wichmann
Journal:  Hum Vaccin Immunother       Date:  2012-09-07       Impact factor: 3.452

9.  Hospital-based surveillance for rotavirus gastroenteritis using molecular testing and immunoassay during the 2011 season in Botswana.

Authors:  Henry Welch; Andrew P Steenhoff; Unoda Chakalisa; Tonya Arscott-Mills; Loeto Mazhani; Margaret Mokomane; Sara Foster-Fabiano; Kathleen E Wirth; Andrew Skinn; Jeffrey M Pernica; Marek Smieja; David M Goldfarb
Journal:  Pediatr Infect Dis J       Date:  2013-05       Impact factor: 2.129

10.  Impact of rotavirus vaccine on premature infants.

Authors:  Jean-Michel Roué; Emmanuel Nowak; Grégoire Le Gal; Thomas Lemaitre; Emmanuel Oger; Elise Poulhazan; Jean-Dominique Giroux; Armelle Garenne; Arnaud Gagneur
Journal:  Clin Vaccine Immunol       Date:  2014-07-30
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.